Carbamic Acid

Carbamic Acid

SCHEMBL4623322

NC(=O)O.O=C(O)Nc1ccccc1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.61
TSHR P16473 2/20 0.61
EPHX2 P34913 2/20 0.61
EPHX1 P07099 1/20 0.61
CDK9 P50750 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
CLK4 Q9HAZ1 1/20 0.61
GAA P10253 1/20 0.59
MAPT P10636 1/20 0.59
GFER P55789 1/20 0.59
HSD17B10 Q99714 2/20 0.56
ALDH1A1 P00352 1/20 0.56
TYR P14679 1/20 0.56
TAS2R38 P59533 1/20 0.56
NAPRT Q6XQN6 1/20 0.56
KDM1A O60341 1/20 0.53
CASP3 P42574 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
TGM2 P21980 2/20 0.50
F13A1 P00488 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbamic Acid SCHEMBL11084365 0.98 TP53 (0.58) TP53TSHREPHX2EPHX1CDK9
Hydroxyamine SCHEMBL5622599 0.92 EPHX2 (0.64) TP53TSHREPHX2EPHX1CDK9
Hydrazine SCHEMBL5624205 0.92 TP53 (0.64) TP53TSHREPHX2EPHX1CDK9
SCHEMBL7634 0.92 EPHX2 (0.70) TP53TSHREPHX2EPHX1CDK9
Benzene SCHEMBL28162617 0.92 EPHX2 (0.70) TP53TSHREPHX2EPHX1CDK9
SCHEMBL11018412 0.91 TP53 (0.56) TP53TSHREPHX2EPHX1CDK9
Phenylurea SCHEMBL28265514 0.91 GAA (0.73) TP53TSHREPHX2EPHX1CDK9
Iodide SCHEMBL5706290 0.90 EPHX2 (0.67) TP53TSHREPHX2EPHX1CDK9
SCHEMBL11353365 0.90 EPHX2 (0.67) TP53TSHREPHX2EPHX1CDK9
Fluoride SCHEMBL10885265 0.90 EPHX2 (0.67) TP53TSHREPHX2EPHX1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1420013-B1 Process for hydrogenating aromatic urethanes in the presence of a supported ruthenium catalyst EVONIK DEGUSSA GMBH (DE) 2008-04-02 EP claimed
EP-1420012-B1 Process for the preparation of aliphatic isocyanates from aromatic isocyanates DEGUSSA (DE) 2006-11-02 EP claimed
US-6924385-B2 Method for synthesis of aliphatic isocyanates from aromatic isocyanates DEGUSSA AG (DE) 2005-08-02 US claimed
US-6809215-B2 SUCH AS CONVERSION OF DIBUTYL 4,4'-METHYLENEDICARBANILATE TO DIBUTYL 4,4'-METHYLENEDICYCLOHEXYLCARBAMATE WITH LOW TRANS-TRANS ISOMER CONTENT DEGUSSA AG (DE) 2004-10-26 US claimed
US-20040097752-A1 Method for synthesis of aliphatic isocyanates from aromatic isocyanates DEGUSSA AG (DE) 2004-05-20 US claimed
US-20040097661-A1 Method for hydrogenation of aromatic urethanes in the presence of a supported rutheniun catalyst DEGUSSA AG (DE) 2004-05-20 US claimed
CN-117106337-A Preparation method of starch-based 3D printing ink suitable for high printability 江南大学 2023-11-24 CN disclosed
CN-116768763-A Preparation method and application of alicyclic carbamate 中国科学院过程工程研究所 2023-09-19 CN disclosed
WO-2023119900-A1 PHOTOSENSITIVE RESIN COMPOSITION AND COLOR FILTER 株式会社レゾナック 2023-06-29 WO disclosed
US-6924385-B2 Method for synthesis of aliphatic isocyanates from aromatic isocyanates DEGUSSA AG (DE) 2005-08-02 US disclosed
US-6809215-B2 SUCH AS CONVERSION OF DIBUTYL 4,4'-METHYLENEDICARBANILATE TO DIBUTYL 4,4'-METHYLENEDICYCLOHEXYLCARBAMATE WITH LOW TRANS-TRANS ISOMER CONTENT DEGUSSA AG (DE) 2004-10-26 US disclosed
US-20040097752-A1 Method for synthesis of aliphatic isocyanates from aromatic isocyanates DEGUSSA AG (DE) 2004-05-20 US disclosed
US-20040097661-A1 Method for hydrogenation of aromatic urethanes in the presence of a supported rutheniun catalyst DEGUSSA AG (DE) 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097752-A1 Method for synthesis of aliphatic isocyanates from aromatic isocyanates DBI, ALKBH3, ECI1 TP53 3043/4885TSHR 4617/4885EPHX2 1125/4885
US-20040097661-A1 Method for hydrogenation of aromatic urethanes in the presence of a supported rutheniun catalyst HRH4, BET1, HRH3 TP53 3353/4885TSHR 4217/4885EPHX2 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.